Keryx Biopharmaceuticals (NASDAQ: KERX) Responds To Erroneous Report About Planned Phase III Study For Patients With Colorectal Cancer

Main Category: Colorectal Cancer
Also Included In: Cancer / Oncology;  Clinical Trials / Drug Trials
Article Date: 08 Feb 2010 - 3:00 PDT

email to a friend   printer friendly   opinions  

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting that Keryx Biopharmaceuticals (NASDAQ: KERX) was mentioned in a published article which contained an inaccurate statement regarding the design of a pending Phase III study for patients with metastatic colorectal cancer.

Keryx CEO Ron Bentsur spoke to BioMedReports and has noted on record that it is estimated that approximately 50% to 60% of mCRC patients are KRAS positive, so that only this sub-group would potentially benefit from receiving an EGFR antibody such as Erbitux or Vectibix, while the remaining 40% to 50% of mCRC patients do not receive EGFR inhibitors.

Based on these statistics, Keryx estimates that only 50% to 60% of the patients to be enrolled in its upcoming Phase 3 trial for perifosine in metastatic colorectal cancer will have received and failed treatment by either Erbitux or Vectibix, which is similar to the patient population in the Keryx Phase 2 study, as well as the general population.

In summary, the pending Phase 3 study and the Phase 2 study populations will be virtually the same.

A complete report on the company is available now at BioMedReports.Com

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here.

Source
BioMedReports.Com

• Additional
• References
• Citations